Last reviewed · How we verify
Umeclidinium / Vilanterol Dry Powder Inhaler
Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that further dilates airways; together they provide sustained bronchodilation for COPD.
Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to relax airway smooth muscle, while vilanterol is a long-acting beta-2 agonist that further dilates airways; together they provide sustained bronchodilation for COPD. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | Umeclidinium / Vilanterol Dry Powder Inhaler |
|---|---|
| Also known as | Anora Ellipta |
| Sponsor | Gary L. Pierce |
| Drug class | Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) |
| Target | M3 muscarinic receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Umeclidinium competitively antagonizes M3 muscarinic receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and promoting smooth muscle relaxation. The dual mechanism provides complementary and sustained airway dilation over 24 hours.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Tachycardia
- Dry mouth
- Urinary retention
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators (PHASE4)
- Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes. (PHASE4)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: